{"product_id":"biolegend-505826","title":"Biolegend, 505826, PE\/Cyanine7 anti-mouse IFN-γ Antibody, 100μg","description":"\u003cp\u003eIFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: E. coli-expressed, recombinant mouse IFN-γ\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE\/Cyanine7 under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702\/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)\u003cbr\u003e\nProduct Citations: Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed He Y, et al. 2022. Adv Healthc Mater. 11:e2200905. PubMed Guo A, et al. 2022. Nature. 607:135. PubMed Kedmi R, et al. 2022. Nature. 610:737. PubMed Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Qiu C, et al. 2022. Front Bioeng Biotechnol. 10:1027619. PubMed Wilson NG, et al. 2023. iScience. 26:105991. PubMed Le DT, et al. 2023. iScience. 26:106059. PubMed Lo WL, et al. 2023. Nat Immunol. 24:676. PubMed Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed Ma X, et al. 2023. Nat Commun. 14:1606. PubMed Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed Chae CS, et al. 2022. Cancer Discov. 12:1904. PubMed Wanhainen KM, et al. 2022. Cancer Immunol Res. 10:871. PubMed Wu J, et al. 2023. Bioact Mater. 20:259. PubMed Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed Ge Y, et al. 2022. iScience. 25:105437. PubMed Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed Blomberg OS 2023. Cancer Cell. 41(1):106-123.e10. PubMed Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed Li H, et al. 2023. Front Immunol. 13:1056447. PubMed Wu B, et al. 2023. J Immunother Cancer. 11: . PubMed Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed Zander R, et al. 2022. Immunity. 55:475. PubMed Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed Nakata J, et al. 2018. Oncotarget. 9:36029. PubMed He Y, et al. 2021. Infect Immun. 89:. PubMed Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed Zhao B, et al. 2020. Nat Commun. 11:908. PubMed Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed Saito S, et al. 2020. Nutrients. 12:. PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Kosack L, et al. 2017. Sci Rep. 7:11289. PubMed Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed Linnerbauer M, et al. 2022. Front Immunol. 12:800128. PubMed Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed Marangoni F, et al. 2021. Cell. . PubMed Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed Lercher A, et al. 2019. Immunity. 51:1074. PubMed Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed Zhan Y, et al. 2021. JCI Insight. 6:. PubMed Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed Glennie N, et al. 2015. J Exp Med. 212: 1405-1414. PubMed Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed Devos M, et al. 2020. J Exp Med. 217:00:00. PubMed Voisinne G, et al. 2022. Nat Immunol. 23:1355. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Shiomi A, et al. 2014. J Immunol. 193:849. PubMed Sawant D, et al. 2014. J Immunol. 192:2904. PubMed Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed Deng Z, et al. 2017. Oncogene. 36:639. PubMed Colliou N, et al. 2018. Gut Microbes. 9:279. PubMed Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed Cho S, et al. 2017. Sci Rep. 7:35. PubMed Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed Ma W, et al. 2017. Sci Rep. . 10.1038\/s41598-017-15661-6. PubMed Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed Xu S, et al. 2021. Immunity. . PubMed Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed Jiang J, et al. 2017. Arthritis Res Ther. 10.1186\/s13075-017-1261-9. PubMed Meadows D, et al. 2015. PLoS One. 10: 0143738. PubMed Burrack K, et al. 2015. J Immunol. 194:678. PubMed Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed Wu B, et al. 2020. Int J Biol Sci. 16:1526. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed Fu S, et al. 2020. Nat Commun. 0.7625. PubMed Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed Holm J, et al. 2015. PLoS One. 10:125495. PubMed Abhyankar MM, et al. 2018. NPJ Vaccines. 3:22. PubMed Zhou J, et al. 2022. Int J Oncol. 61: . PubMed Friedman R, et al. 2014. Proc Natl Acad Sci U S A. 111:9223. PubMed Huang H, et al. 2021. Cell. 184(5):1245-1261.e21. PubMed Li C, et al. 2018. Cell. 174:285. PubMed Resende M, et al. 2019. J Immunol. 203:2451. PubMed Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed Minns D, et al. 2021. Nat Commun. 12:1285. PubMed Dhar P, et al. 2021. Commun Biol. 4:905. PubMed Roy S, et al. 2021. Nat Commun. 12:3182. PubMed Sun X, et al. 2021. Nature. 599:673. PubMed Zhao X, et al. 2022. iScience. 25:104690. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Sun X, et al. 2017. Microbes Infect. 10.1016\/j.micinf.2017.08.007. PubMed Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed Wen J, et al. 2015. J Pharmacol Sci. 128: 116-124. PubMed Imbratta C, et al. 2019. Sci Rep. 9:6135. PubMed Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed Zhang M, et al. 2022. iScience. 25:104490. PubMed Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed Wolf Y, et al. 2019. Cell. 179:219. PubMed Omenetti S, et al. 2019. Immunity. 51:77. PubMed Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed\u003cbr\u003e\nRRID: AB_1595591 (BioLegend Cat. No. 505825) AB_2295770 (BioLegend Cat. No. 505826)\u003cbr\u003e\nStructure: Cytokine; dimer; 40-80 kD (Mammalian)\u003cbr\u003e\nBioactivity: Antiviral\/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.\u003cbr\u003e\nRegulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone\u003cbr\u003e\nGene ID: 15978\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nClone: XMG1.2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864100163753,"sku":"505826","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-505826","provider":"Iright","version":"1.0","type":"link"}